{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:56:30Z","timestamp":1787871390433,"version":"build-2784847793"},"reference-count":44,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2019,1,6]]},"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The outcome of participants with nephrotic syndrome in clinical trials of lupus nephritis has not been studied in detail.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Collated data from two randomised controlled trials in lupus nephritis, Lupus Nephritis Assessment of Rituximab (LUNAR) and A Study to Evaluate Ocrelizumab in Patients With Nephritis due to Systemic Lupus Erythematosus (BELONG) were analysed. Nephrotic syndrome was defined as albumin &lt;3\u2009g\/dL and urine protein\/creatinine ratio \u22653.5\u2009g\/g at start of trial. Renal response was defined as a first morning urine protein\/creatinine ratio \u22640.5\u2009g\/g in addition to \u226425% increase in creatinine from trial entry assessed at week 48. Logistic regression was used to evaluate the association of nephrotic syndrome with renal response while adjusting for treatment received and ACE inhibitor or angiotensin receptor blocker use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>28 (26%) participants with nephrotic syndrome achieved renal response as compared with 130 (52.5%) of those without (p&lt;0.001). Having nephrotic syndrome at baseline significantly lowered the likelihood of achieving renal response (OR 0.32, 95 % CI 0.19 to 0.54, p&lt;0.001). 125 (80%) participants achieved resolution of their nephrotic syndrome in a median time of 16 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Nephrotic syndrome at baseline decreases the likelihood of renal response at 1\u2009year. Longer clinical trials or better short-term predictors of long-term outcomes may better assess the effect of novel therapeutic approaches on subjects with nephrotic syndrome.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/lupus-2018-000308","type":"journal-article","created":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T12:15:33Z","timestamp":1549282533000},"page":"e000308","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis"],"prefix":"10.1136","volume":"6","clinical-trial-number":[{"clinical-trial-number":"nct00282347","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00626197","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Liliana Michelle","family":"Gomez Mendez","sequence":"first","affiliation":[{"name":"Department of Pediatric Nephrology, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D","family":"Cascino","sequence":"additional","affiliation":[{"name":"Product Development Clinical Science, Genentech Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamiko R","family":"Katsumoto","sequence":"additional","affiliation":[{"name":"Product Development Clinical Science, Genentech Inc, South San Francisco, California, USA"},{"name":"Early Development, Genentech Inc, South San Francisco, CA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Brakeman","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Brunetta","sequence":"additional","affiliation":[{"name":"Product Development Clinical Science, Genentech Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jayne","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Dall\u2019Era","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of California San Francisco, San Francisco, CA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Rovin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine\/Nephrology, Ohio State University Wexner Medical Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Garg","sequence":"additional","affiliation":[{"name":"Product Development Clinical Science, Genentech Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,2,4]]},"reference":[{"key":"2025091513363095000_6.1.e000308.1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014030267"},{"key":"2025091513363095000_6.1.e000308.2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.10131011"},{"key":"2025091513363095000_6.1.e000308.3","doi-asserted-by":"publisher","DOI":"10.2174\/157016111203140518172048"},{"key":"2025091513363095000_6.1.e000308.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199804233381707"},{"key":"2025091513363095000_6.1.e000308.5","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2003.09.011"},{"key":"2025091513363095000_6.1.e000308.6","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313492576"},{"key":"2025091513363095000_6.1.e000308.7","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-011-0434-0"},{"key":"2025091513363095000_6.1.e000308.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.66027.x"},{"key":"2025091513363095000_6.1.e000308.9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.reuma.2013.09.005","article-title":"Predictive risk factors for failure to induction therapy of lupus nephritis in a cohort of Colombian patients","volume":"10","author":"Pinto Pe\u00f1aranda","year":"2014","journal-title":"Reumatolog\u00eda Cl\u00ednica"},{"key":"2025091513363095000_6.1.e000308.10","doi-asserted-by":"publisher","DOI":"10.1177\/0961203314558857"},{"key":"2025091513363095000_6.1.e000308.11","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002520","article-title":"Pentraxin 3 is closely associated with tubulointerstitial injury in lupus nephritis: a large multicenter cross-sectional study","volume":"95","author":"Pang","year":"2016","journal-title":"Medicine"},{"key":"2025091513363095000_6.1.e000308.12","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313502864"},{"key":"2025091513363095000_6.1.e000308.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206456"},{"key":"2025091513363095000_6.1.e000308.14","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1517-0"},{"key":"2025091513363095000_6.1.e000308.15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.5114\/ceji.2014.43730","article-title":"Clinical immunology relationship between hypoalbuminemia, hyperlipidemia and renal severity in patients with lupus nephritis: a prospective study","volume":"2","author":"Sui","year":"2014","journal-title":"Cejoi"},{"key":"2025091513363095000_6.1.e000308.16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102533"},{"key":"2025091513363095000_6.1.e000308.17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1586\/1744666X.2015.990883","article-title":"The multifaceted aspects of refractory lupus nephritis","volume":"11","author":"Moroni","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"2025091513363095000_6.1.e000308.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.08.002"},{"key":"2025091513363095000_6.1.e000308.19","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.06720615"},{"key":"2025091513363095000_6.1.e000308.20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket491"},{"key":"2025091513363095000_6.1.e000308.21","doi-asserted-by":"publisher","DOI":"10.1159\/000089843"},{"key":"2025091513363095000_6.1.e000308.22","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313477225"},{"key":"2025091513363095000_6.1.e000308.23","doi-asserted-by":"publisher","DOI":"10.1191\/0961203306lu2264oa"},{"key":"2025091513363095000_6.1.e000308.24","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013010026"},{"key":"2025091513363095000_6.1.e000308.25","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfp427"},{"key":"2025091513363095000_6.1.e000308.26","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000108969.21691.5D"},{"key":"2025091513363095000_6.1.e000308.27","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130005"},{"key":"2025091513363095000_6.1.e000308.28","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr741"},{"key":"2025091513363095000_6.1.e000308.29","doi-asserted-by":"publisher","DOI":"10.1002\/art.20666"},{"key":"2025091513363095000_6.1.e000308.30","doi-asserted-by":"publisher","DOI":"10.1002\/art.34359"},{"key":"2025091513363095000_6.1.e000308.31","doi-asserted-by":"publisher","DOI":"10.1002\/art.38037"},{"key":"2025091513363095000_6.1.e000308.32","doi-asserted-by":"publisher","DOI":"10.1002\/art.10461"},{"key":"2025091513363095000_6.1.e000308.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.10.009"},{"key":"2025091513363095000_6.1.e000308.34","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.091028"},{"key":"2025091513363095000_6.1.e000308.35","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh719"},{"key":"2025091513363095000_6.1.e000308.36","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10157-013-0841-5","article-title":"Lower serum albumin level is associated with higher fractional excretion of creatinine","volume":"18","author":"Horio","year":"2014","journal-title":"Clin Exp Nephrol"},{"key":"2025091513363095000_6.1.e000308.37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clim.2016.09.002","article-title":"Anti-dsDNA antibodies and resident renal cells - Their putative roles in pathogenesis of renal lesions in lupus nephritis","volume":"185","author":"Yung","year":"2017","journal-title":"Clin Immunol"},{"key":"2025091513363095000_6.1.e000308.38","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05080610"},{"key":"2025091513363095000_6.1.e000308.39","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002628"},{"key":"2025091513363095000_6.1.e000308.40","first-page":"1","article-title":"Kinetics of rituximab excretion into urine and peritoneal fluid in two patients with nephrotic syndrome","volume":"2017","author":"Stahl","year":"2017","journal-title":"Case Rep Nephrol"},{"key":"2025091513363095000_6.1.e000308.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2017.09.001"},{"key":"2025091513363095000_6.1.e000308.42","doi-asserted-by":"crossref","first-page":"CJN.01070118","DOI":"10.2215\/CJN.01070118","article-title":"Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis","volume":"13","author":"Gomez Mendez","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025091513363095000_6.1.e000308.43","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200406000-00011"},{"key":"2025091513363095000_6.1.e000308.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2008.03.003"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2018-000308","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T20:36:37Z","timestamp":1757968597000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2018-000308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,2,4]]},"published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1136\/lupus-2018-000308"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2018-000308","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}